Financing and making business value visible through the separation of the cell therapy business into a newly established company
First written in FY2024-Q3. 1 of 2 entries say "Advanced", first in FY2025-H1. Latest entry: FY2025-H1.
No other company in this theme has enough history to compare yet.
- FY2025-H1AdvancedAnnual report
「Effective 1 April this year, the Company spun off its cell therapy business as S-Quatre, a wholly owned subsidiary. As a result, the Company and S-Quatre each adopted a structure focused exclusively on the biosimilars business and the cell therapy business, respectively.」
The Company spun off the cell therapy business as S-Quatre on 1 April 2024 and implemented a structural reform under which the biosimilars business and cell therapy business would each focus exclusively on its respective area. Discussions also began on diversifying fundraising methods and increasing the visibility of business value. - FY2024-Q3First statedAnnual report
「As stated in the notice concerning the establishment of a subsidiary through a company split (simplified incorporation-type company split) for the cell therapy business (regenerative medicine), announced on 12 January 2024, the Company decided to transfer its cell therapy business (regenerative medicine) through a company split to a newly established company scheduled to be incorporated on 1 April 2024. The business is being separated into an independent newly established company to facilitate efficient fundraising and business development and to further improve the visibility of its business value.」
The initiative to separate the cell therapy business into S-Quatre, scheduled to be incorporated on 1 April 2024, and pursue optimization of management resources, diversification of fundraising methods and greater visibility into business value through both the Company, centered on the biosimilars business, and the newly established company specializing in cell therapy, appeared for the first time.